RNOtherRevista latino-americana de enfermagem2016

Potential drug interactions in patients given antiretroviral therapy.

Wendel Mombaque Dos Santos, Silvia Regina Secoli, Stela Maris de Mello Padoin

PMID 27878224

WHAT IT FOUND

Over half of patients on HIV therapy had potential drug interactions.

Taking five or more medicines or being on treatment for six years or more significantly raised this risk. Nurses should check for polypharmacy and long-term use to catch dangerous combinations.

Key findings

0152.2% of the 161 patients were exposed to potential drug-drug interactions.

02Polypharmacy and treatment duration were significantly associated with the presence of drug interactions.

03Ritonavir was the antiretroviral involved in the most interactions, followed by diazepam among central nervous system drugs.

STILL TO COME

How it was doneWhat they foundWhat it means for RNs

Read the rest of this summary

You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.

Already have one?

What it does not show

The study used a convenience sample from a single clinic, which limits how much the results apply to other populations. Researchers did not perform an individual clinical evaluation of the risks and benefits of the identified interactions. The study relied on a database to identify potential interactions, so it did not measure actual adverse events or outcomes that occurred in these patients. Information on over-the-counter medications, medicinal plants, and some comorbidities was not fully captured, meaning the number of interactions may be underestimated.

Declared interests

The study was approved by the Research Ethics Committee at the Federal University of Santa Maria, Brazil. No specific funding sources or commercial conflicts of interest are declared in the provided text.

The easy way to misread this

Do not assume these are all harmful interactions. About two-fifths of the potential interactions identified were beneficial, such as using ritonavir to boost the levels of other antiretrovirals. The study identified potential risks based on a database, not actual patient harm.

Read it on PubMed →